Biological Characteristics and Effect of Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs) Grafting with Blood Plasma on Bone Regeneration in Rats

Qu, Zhiguo; Guo, Libin; Fang, Guojun; Cui, Zhenghong; Guo, Shengnan; Liu, Ying

doi:10.1007/s12013-012-9354-1

Cited by 14 publications

(19 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PLT-related parameters, including platelet count, volume, mean volume and distribution width decreased post-operation compared to pre-operation. Similar results on safety have been reported in our previous study, in which we injected hUC-MSCs into rats and found hUC-MSCs located in the rat non-union area that differentiated into osteoblasts, as well as no local or systematic manifestations of toxic reactions and graft vs. host disease during and after transplantation (11,12). Based on the above results, this approach is relatively safe.…”

Section: Discussionsupporting

confidence: 89%

Efficacy of umbilical cord-derived mesenchymal stem cell-based therapy for osteonecrosis of the femoral head: A three-year follow-up study

Chen

Yin

et al. 2016

Molecular Medicine Reports

Self Cite

View full text Add to dashboard Cite

This is a retrospective analysis of the clinical effects of transplant of mesenchymal stem cells (MSCs) derived from human umbilical cord-derived MSCs (hUC-MSCs) for the treatment of osteonecrosis of the femoral head (ONFH). The biological characteristics of hUC-MSCs were assessed using flow cytometry. Nine eligible patients were enrolled in the study as they adhered to the Association Research Circulation Osseous (ARCO) classification of stage II–IIIa, and hUC-MSCs were grafted by intra-arterial infusion. Organize effective perfusion was assessed using the oxygen delivery index (ODI). The results showed that the ODI was increased at three days post-operation. The MRI results revealed that at 12 and 24 months after treatment, the necrotic volume of the femoral heads was significantly reduced. No obvious abnormalities were observed. Taken together, these data indicate that intra-arterially infused hUC-MSCs migrate into the necrotic field of femoral heads and differentiate into osteoblasts, thus improving the necrosis of femoral heads. This finding suggested that intra-arterial infusion of hUC-MSCs MSCs is a feasible and relatively safe method for the treatment of femoral head necrosis.

show abstract

Section: Discussionsupporting

confidence: 89%

Efficacy of umbilical cord-derived mesenchymal stem cell-based therapy for osteonecrosis of the femoral head: A three-year follow-up study

Chen

Yin

et al. 2016

Molecular Medicine Reports

Self Cite

View full text Add to dashboard Cite

show abstract

“…Guillot PV et al, using a mouse model of OI, have demonstrated that there existed a clinically relevant reduction in incidence rate of bone fracture and huge improvement in the reparative bone tissue with the transplantation of hUC-MSCs [25] . In the stem cell transplantation groups, autologous hUC-MSCs had differentiated into bone cells and large numbers of new multi-center bone growth occurred, highlighting their therapeutic potential for bone repair and healing [14,21,28] .…”

Section: Prospect Of Bone Repair and Healingmentioning

confidence: 99%

“…In additional, hUC-MSCs shared most of the features with MSC from bone marrow, including their morphology and biological characteristics [10] . A great quantity of evidence showed that hUC-MSCs have great potential for self-renewal and multipotential differentiation, which can be differentiated into osteogenic cells, adipogenic cells, neural cells, cartilage cells and others under specific induction of certain factors or stimulation [12][13][14] .…”

Section: Introductionmentioning

confidence: 99%

“…Compared with BMSCs, hUC-MSCs have more distinct advantages, such as accessibility, their little ethical constraints, painless and time-saved procedures involved, higher proliferation capacity, long term preservation, lower risk of immune rejection and viral contamination [14][15][16][17][18] . Moreover, numerous umbilical cord blood banks worldwide have been established to rapidly increase the supply of hUC-MSCs for cell-based therapy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Unique Features and Clinical Application Prospect of Human Umbilical Cord Mesenchymal Stem Cells

Dilxat¹,

Li²,

Liu³

2016

International Journal of Orthopaedics

View full text Add to dashboard Cite

MSCs. Moreover, MSCs harvested from hUC are pluripotent and immunologically naive. The morphology and biological characteristic of hUC-MSCs resembles that of MSCs isolated from bone marrow. CONCLUSION: Cell-based therapy is an emerging field, which can offer great therapeutic potential in the complex human diseases. Compared with bone marrow, hUC has been considered as an ideal source of MSCs due to their little ethical obstacles, painless procedures involved, lower risk of immune rejection and convenient sources for autologous cell therapy. The rapid development of umbilical cord blood banks appears to provide plentiful supply of stem cells for regenerative medicine and tissue engineering. INTRODUCTIONWith the increasing prevalence and incidence rates in the complex human diseases, e.g., bone regeneration disease, cardiovascular disease, diabetic disease and hematopoietic disease, there exits an urgent need to search for more effective and efficient therapies. Cellbased therapy is a novel and potential therapeutic approach, which can replace diseased or damaged cells with minimal side effects by introducing stem cells to these tissues or organs [1][2][3][4] . Currently, BMSCs have represented the golden type of stem cell for cell-based therapies. Experimental and clinical studies have showed the selfrenewal and multilineage differentiation capability of BMSCs [5][6][7] . However, it is quite difficult to produce large quantities of tissue/cells via bone marrow due to the decreasing frequency and differentiation potential with age. The harvesting of BMSCs also involves invasive procedures [8] . Therefore, the search for substitute of BMSCs is of ABSTRACT AIM: The purpose of the study was to summarize the unique features of human umbilical cord mesenchymal stem cells (hUC-MSCs) and their clinical application prospect.

show abstract

“…MSCs can be isolated from various tissues, including bone marrow, adipose tissue, synovium, periosteum, skeletal muscles, and umbilical cord tissues (8). In previous studies, we demonstrated the immunologic compatibility and osteogenic properties of human umbilical cord-derived mesenchymal stem cells (Hu-MSCs)in tibia non-union in rats (9,10) and patients (11). The primary aim of the present study was to examine in cerebral hemorrhage both with bone marrow mononuclear cells/Hu-MSCs and with conventional surgical approaches, which enhanced regenerative support from transplanted cells to effectively treat acute and chronic disorders of the nervous system.…”

Section: Introductionmentioning

confidence: 99%

Cell therapy for cerebral hemorrhage: Five year follow-up report

Chang

Mao²,

Sun³

et al. 2016

Experimental and Therapeutic Medicine

Self Cite

View full text Add to dashboard Cite

The aim of the study was to examine treatment of cerebral hemorrhages with bone-marrow or human umbilical cord-derived mesenchymal stem cells (BMSCs or Hu-MSCs) and conventional surgical approaches, and determine and compare the effectiveness, feasibility, safety and reproducibility of each method. A retrospective analysis was performed on a cohort of cell-treated cerebral hemorrhage patients from October 1, 2007 to October 1, 2009. A total of 24 patients, all of whom received conventional surgical treatment, were classified as follows: i) The control group consisted of 8 patients who received only hematoma removal surgery, ii) the autologous group consisted of 7 patients who received additional autologous bone marrow mononuclear cell transplantation, and iii) the allograft group consisted of 9 patients who received additional umbilical cord mononuclear cell transplantation. After conventional hematoma removal surgery and X-ray supervision within 24 h and at 7 days, neurological disability and function tests were completed 3, 6, 12, 36 and 60 months later. The T-cell marker plasma levels were analyzed after 60 months. The results showed that, at approximately 3.5 months after graft the hematomas in all the groups were completely reabsorbed as observed on computed tomography scans. However, the functional outcomes in the cell-transplanted groups were better than in the control group after 5 years. While the National Institutes of Health Stroke Scale, modified Rankin score and modified Barthel index scores were simliar in the cell-transplanted groups, patients in the allograft group had better outcomes than those in the autologous graft group starting at 3 months and until the end of the follow-up period. The serum levels of T-cell markers CD4, CD56 and human leukocyte antigen-DR in the allograft group showed no signs of immunogenic graft complications and there were no significant differences in T-cell subtypes among the patient groups. The results of the present study suggest that, treatment of cerebral hemorrhage patients can be safely and effectively accomplished using Hu-MSC grafting and larger clinical trials should be considered in the future.

show abstract

Biological Characteristics and Effect of Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs) Grafting with Blood Plasma on Bone Regeneration in Rats

Cited by 14 publications

References 17 publications

Efficacy of umbilical cord-derived mesenchymal stem cell-based therapy for osteonecrosis of the femoral head: A three-year follow-up study

Efficacy of umbilical cord-derived mesenchymal stem cell-based therapy for osteonecrosis of the femoral head: A three-year follow-up study

Unique Features and Clinical Application Prospect of Human Umbilical Cord Mesenchymal Stem Cells

Cell therapy for cerebral hemorrhage: Five year follow-up report

Contact Info

Product

Resources

About